Lia Tsimberidou, MD, PhD

Lia Tsimberidou, MD, PhD

Tenured Associate Professor
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Related Videos

What is the risk of not performing comprehensive NGS molecular profiling, and relying exclusively on more targeted panels? What might we miss? Video

What is the risk of not performing comprehensive NGS molecular profiling, and relying exclusively on more targeted panels? What might we miss?

What is the risk of not performing comprehensive NGS molecular profiling, and relying exclusively on more targeted panels? What might we miss?

Although you work in a tertiary cancer referral and research center where many patients have advanced disease, at what point in the natural history of cancer do you think is the ideal time to perform NGS? Video

Although you work in a tertiary cancer referral and research center where many patients have advanced disease, at what point in the natural history of cancer do you think is the ideal time to perform NGS?

Although you work in a tertiary cancer referral and research center where many patients have advanced disease, in general, at what point in the natural history of cancer do you think is the ideal time to perform NGS?

Can you share a case history of a patient who was failing multiple, standard therapies and then responded to treatment based on NGS profiling? Video

Can you share a case history of a patient who was failing multiple, standard therapies and then responded to treatment based on NGS profiling?

Can you share a case history of a patient who was failing multiple, standard therapies and then responded to treatment based on NGS profiling?

Can you give us patient-specific examples that demonstrate the potential clinical benefits -- improvements in PFS, OS and other metrics -- of whole exome, hybrid capture-based NGS? Video

Can you give us patient-specific examples that demonstrate the potential clinical benefits -- improvements in PFS, OS and other metrics -- of whole exome, hybrid capture-based NGS?

Can you give us patient-specific examples that demonstrate the potential clinical benefits — improvements in PFS, OS and other metrics — of whole exome, hybrid capture-based NGS?

How do you identify patients with targetable alterations that would suggest their triage into clinical trials? Video

How do you identify patients with targetable alterations that would suggest their triage into clinical trials?

How do you identify patients with targetable alterations that would suggest their triage into clinical trials?

How do you approach drug selection decisions when you encounter multiple actionable targets? Video

How do you approach drug selection decisions when you encounter multiple actionable targets?

How do you approach drug selection decisions when you encounter multiple actionable targets?

Do mutational targets in solid tumors change over time, and does this justify multiple biopsies and repeat NGS-based profiling in the case of progressive disease to identify new drivers? Video

Do mutational targets in solid tumors change over time, and does this justify multiple biopsies and repeat NGS-based profiling in the case of progressive disease to identify new drivers?

Do mutational targets in solid tumors change over time, and does this justify multiple biopsies and repeat NGS-based profiling in the case of progressive disease to identify new drivers that may have treatment implications?

At what stage of a cancer's presentation is the oncologist advised to deploy genomic profiling to inform clinical decision-making and therapeutic choices aligned with specific alterations and mutations? Video

At what stage of a cancer's presentation is the oncologist advised to deploy genomic profiling to inform clinical decision-making and therapeutic choices aligned with specific alterations and mutations?

At what stage of a cancer’s presentation or evolution is the oncologist advised to deploy genomic profiling to inform clinical decision-making and therapeutic choices aligned with specific alterations and mutations?

How do we curate the results of NGS-based genomic profiles? How do we prioritize subsidiary molecular markers, especially when there are multiple drivers identified, and determine their level of actionability? Video

How do we curate the results of NGS-based genomic profiles? How do we prioritize subsidiary molecular markers, especially when there are multiple drivers identified, and determine their level of actionability?

How do we curate the results of NGS-based genomic profiles? In particular, how do we prioritize subsidiary molecular markers, especially when there are multiple drivers identified, and determine their level of actionability? Is there a ...